Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

Abstract To find metastatic recurrence biomarkers of triple-negative breast cancer (TNBC) treated by neoadjuvant chemotherapy and anti-EGFR antibodies (NAT), we evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nanostring technology, and TIL assessmen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nina Radosevic-Robin, Pier Selenica, Yingjie Zhu, Helen H. Won, Michael F. Berger, Lorenzo Ferrando, Emiliano Cocco, Maud Privat, Flora Ponelle-Chachuat, Catherine Abrial, Jean-Marc Nabholtz, Frederique Penault-Llorca, Jorge S. Reis-Filho, Maurizio Scaltriti
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5085bbfc4563442588c40da205b8c222
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5085bbfc4563442588c40da205b8c222
record_format	dspace
spelling	oai:doaj.org-article:5085bbfc4563442588c40da205b8c2222021-12-02T18:02:32ZRecurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies10.1038/s41523-021-00334-52374-4677https://doaj.org/article/5085bbfc4563442588c40da205b8c2222021-09-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00334-5https://doaj.org/toc/2374-4677Abstract To find metastatic recurrence biomarkers of triple-negative breast cancer (TNBC) treated by neoadjuvant chemotherapy and anti-EGFR antibodies (NAT), we evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nanostring technology, and TIL assessment on H&E. Six patients experienced a rapid fatal recurrence (RR) and other 6 had later non-fatal recurrences (LR). Before NAT, RR had low expression of 6 MHC class I and 13 MHC class II genes but were enriched in upregulated genes involved in the cell cycle-related pathways. Their TIL number before NAT in RR was very low (<5%) and did not increase after treatment. In post-NAT residual tumors, RR cases showed high expression of SOX2 and CXCR4. Our results indicate that high expression of cell cycle genes, combined with cold immunological phenotype, may predict strong TNBC resistance to NAT and rapid progression after it. This biomarker combination is worth validation in larger studies.Nina Radosevic-RobinPier SelenicaYingjie ZhuHelen H. WonMichael F. BergerLorenzo FerrandoEmiliano CoccoMaud PrivatFlora Ponelle-ChachuatCatherine AbrialJean-Marc NabholtzFrederique Penault-LlorcaJorge S. Reis-FilhoMaurizio ScaltritiNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Nina Radosevic-Robin Pier Selenica Yingjie Zhu Helen H. Won Michael F. Berger Lorenzo Ferrando Emiliano Cocco Maud Privat Flora Ponelle-Chachuat Catherine Abrial Jean-Marc Nabholtz Frederique Penault-Llorca Jorge S. Reis-Filho Maurizio Scaltriti Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
description	Abstract To find metastatic recurrence biomarkers of triple-negative breast cancer (TNBC) treated by neoadjuvant chemotherapy and anti-EGFR antibodies (NAT), we evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nanostring technology, and TIL assessment on H&E. Six patients experienced a rapid fatal recurrence (RR) and other 6 had later non-fatal recurrences (LR). Before NAT, RR had low expression of 6 MHC class I and 13 MHC class II genes but were enriched in upregulated genes involved in the cell cycle-related pathways. Their TIL number before NAT in RR was very low (<5%) and did not increase after treatment. In post-NAT residual tumors, RR cases showed high expression of SOX2 and CXCR4. Our results indicate that high expression of cell cycle genes, combined with cold immunological phenotype, may predict strong TNBC resistance to NAT and rapid progression after it. This biomarker combination is worth validation in larger studies.
format	article
author	Nina Radosevic-Robin Pier Selenica Yingjie Zhu Helen H. Won Michael F. Berger Lorenzo Ferrando Emiliano Cocco Maud Privat Flora Ponelle-Chachuat Catherine Abrial Jean-Marc Nabholtz Frederique Penault-Llorca Jorge S. Reis-Filho Maurizio Scaltriti
author_facet	Nina Radosevic-Robin Pier Selenica Yingjie Zhu Helen H. Won Michael F. Berger Lorenzo Ferrando Emiliano Cocco Maud Privat Flora Ponelle-Chachuat Catherine Abrial Jean-Marc Nabholtz Frederique Penault-Llorca Jorge S. Reis-Filho Maurizio Scaltriti
author_sort	Nina Radosevic-Robin
title	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
title_short	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
title_full	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
title_fullStr	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
title_full_unstemmed	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
title_sort	recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-egfr antibodies
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5085bbfc4563442588c40da205b8c222
work_keys_str_mv	AT ninaradosevicrobin recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT pierselenica recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT yingjiezhu recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT helenhwon recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT michaelfberger recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT lorenzoferrando recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT emilianococco recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT maudprivat recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT floraponellechachuat recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT catherineabrial recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT jeanmarcnabholtz recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT frederiquepenaultllorca recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT jorgesreisfilho recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies AT maurizioscaltriti recurrencebiomarkersoftriplenegativebreastcancertreatedwithneoadjuvantchemotherapyandantiegfrantibodies
_version_	1718378866150473728

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

Ejemplares similares